China Pharma Holdings, Inc. — FY2016 Form 10-K
Reporting period: Fiscal year ended December 31, 2016; comparative figures are for FY2015. China Pharma develops, manufactures, and sells prescription pharmaceuticals in China, principally through its operating subsidiary, Helpson. The financial statements are presented in U.S. dollars.
Financial performance and position
| Metric | FY2016 / Dec. 31, 2016 | FY2015 / Dec. 31, 2015 |
|---|---|---|
| Revenue | $15.57 million | $20.35 million |
| Gross profit and margin | $3.22 million; 20.7% | $1.46 million; approximately 7.2% |
| Operating loss | $8.16 million | $14.30 million |
| Net loss and diluted loss per share | $9.18 million; $0.21 | $15.41 million; $0.35 |
| Cash from operating activities | $2.90 million | $3.35 million |
| Cash and cash equivalents | $2.67 million | $6.25 million |
| Total assets / total liabilities | $78.52 million / $19.61 million | $96.51 million / $23.87 million |
| Construction loan outstanding | $10.08 million | $12.33 million |
- Revenue fell 23.5%. Anti-infection, respiratory, and antiviral products generated $10.27 million, down 24%; this category contributed 65% of revenue. CNS/cerebral-cardiovascular sales declined 12% to $2.72 million. Digestive-disease revenue was broadly flat at $0.79 million.
- Gross margin improved from 2015, when the company recorded $3.11 million of inventory obsolescence. Management estimates 2015 gross margin excluding that charge was 22.5%, versus 20.7% in 2016.
- Operating expenses included $1.09 million of bad-debt expense and $3.96 million of impairment losses in 2016. The impairment related to advances to five laboratories for drug formulas that management judged unlikely to generate positive cash flow. The 2015 financial statements include $10.15 million of bad-debt expense, including approximately $4.1 million related to supplier advances.
- Net loss narrowed year over year, principally alongside lower bad-debt expense and no inventory-obsolescence expense; the 2016 impairment charge partly offset those improvements. Foreign-currency translation reduced comprehensive income by $4.55 million.
- Operating cash flow was $2.90 million; investing cash outflow was $0.19 million and financing cash outflow was $6.02 million, mainly reflecting repayment of short-term notes and scheduled construction-loan payments. Cash declined by $3.58 million during the year.
- Current assets were $17.52 million and current liabilities $10.40 million. Cash included $1.09 million of restricted cash securing bankers’ acceptance notes. The company said its $2.67 million cash balance was indefinitely reinvested in China and not expected to be available to the parent for dividends or other payments.
- The prior-year $4.62 million short-term bank line was repaid in 2016. The remaining construction loan is secured by the new factory and equipment, bears a rate of 5.39% as of July 2016, and has scheduled principal payments; $1.44 million is due in 2017. A director-related loan of $1.35 million bears 1% interest and was extended to December 31, 2017.
Changes, outlook, and risks
- Management attributed sales weakness to distributor attention being diverted by a CFDA compliance campaign during the second and third quarters, as well as market fluctuations. Sales increased in the fourth quarter compared with the third quarter, according to management, which identified sales promotion and participation in provincial drug tenders as priorities.
- Earlier GMP-related production suspensions and missed provincial drug bids had affected market share and sales. The company reports that its injectable, tablet, capsule, and cephalosporin lines received GMP certification by 2015.
- Generic-drug consistency evaluations and evolving CFDA requirements delayed pipeline approvals. The company suspended pipeline development in 2016 amid uncertainty over implementation rules; it said several candidates required additional trials or evaluation work. The filing does not provide a quantified pipeline revenue forecast or formal earnings guidance.
- Management expected existing resources and operating cash flow to cover working capital and anticipated capital expenditures for at least the next 12 months, but noted that additional financing might be needed if plans or circumstances changed. Approximately $4.4 million of future payments to laboratories and service providers is contingent on completion of contract phases over about four years.
- The company’s preferential 15% tax rate ended after 2016; management expects a 25% rate from 2017. The company also faces pricing and reimbursement pressures, competitive risks, product-approval and consistency-evaluation deadlines, distributor dependence, and restrictions on currency conversion and remittance from China.
- Receivables remain a significant collection risk: one customer represented 46.3% of year-end accounts receivable, and 68.5% of gross receivables were more than 720 days old. No customer represented more than 10% of annual sales.
- Management concluded internal control over financial reporting and disclosure controls were not effective at year-end due to a material weakness: insufficient personnel knowledgeable in U.S. GAAP financial reporting. Management described training and process-review remediation efforts. The auditor gave an unqualified opinion on the financial statements but did not audit or opine on internal-control effectiveness.
- The company reported no legal proceedings believed likely to have a material adverse effect, no off-balance-sheet arrangements, and no plans to pay cash dividends in the foreseeable future.
Important facts for investors to verify
- Whether sales recovered after the 2016 distributor disruption, and how the company’s products perform in subsequent tenders and distribution channels.
- Collectability of aged receivables, particularly the balance due from the customer representing 46.3% of receivables, and the adequacy of the related allowance.
- Progress, costs, and deadlines for consistency evaluations and CFDA approvals; also the status and recoverability of the $35.50 million in advances for intangible assets after the 2016 impairment.
- Liquidity and debt-service capacity, including restricted cash, 2017 loan repayments, the director-related loan maturity, and the contingent $4.4 million of formula-development commitments.
- Whether the internal-control material weakness is remediated and whether the anticipated 25% tax rate affects results as expected.
- Clarification of filing inconsistencies, including the reported outstanding-share date on the cover page and the different descriptions of certain pipeline products and impairment charges in the narrative versus financial-statement notes.